Clinical studies with MTA. by Calvert, A. H. & Walling, J. M.
British Joumal ofCancer (1998) 78(Supplement 3), 35-40
© 1998 Cancer Research Campaign
Clinical studies with MTA
AH Calvert' and JM Walling2
'Division of Oncology, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK; 2Lilly Research Laboratories, Eli Lilly and Co.,
Indianapolis, Indiana 46285-225, USA
Summary MTA (LY231514), a multi-targeted antifolate, is a classical antifolate undergoing intracellular polyglutamation. Polyglutamated
MTA is a potent thymidylate synthase (TS) inhibitor and inhibits other folate-dependent enzymes, including dihydrofolate reductase and
glycinamide ribonucleotide formyl transferase. Multifocal antifolates may overcome antifolate resistance, but it is not known whether the anti-
tumour activity of MTA depends on its TS inhibition, its primary locus of action, or whether other loci contribute. MTA was examined in three
phase trials using different schedules: a 10-min i.v. infusion given once every 3 weeks, once weekly for 4 weeks every 6 weeks or daily for 5
days every 3 weeks. Dose-limiting toxicities were neutropenia and thrombocytopenia. Other consistently seen side-effects, which were
manageable, included mucositis, skin rashes and transient elevations of transaminases. Toxicity was highly schedule dependent: the
recommended dose for the 3-weekly schedule (600 mg m-2) was 30 times that for the daily x 5 schedule (4 mg m-2 day-'). The 3-weekly
dosing schedule was chosen for phase 11 evaluation. Phase II trials are underway to investigate the activity and toxicity of MTA in several
tumour types, including colorectal, pancreas, breast, bladder and non-small-cell lung cancer (NSCLC) Further phase trials will investigate
MTA in combination with other agents, including gemcitabine, cisplatin, 5-fluorouracil and folate. Preliminary phase 11 trials results are
encouraging; responses were seen in colorectal, pancreas, NSCLC and breast cancer.
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The use of antimetabolites in the treatment of cancer was first
explored in 1948 by Farber, who discovered that administration of
aminopterin caused remission in patients suffering from leukaemia
(Farber et al, 1948). Antimetabolites are compounds that either
inhibit the synthesis of the precursors of DNA or, because of their
structural similarity to the natural precursors, are incorporated into
DNA and/or RNA, causing cell death or stasis. Antifolates can
inhibit specifically the synthesis of the pyrimidine or purine bases
required for DNA synthesis, as several ofthe enzymes required for
the synthesis of these are folate dependent. As cancer cells are
actively proliferating, they require large quantities of DNA and
RNA. This makes them susceptible targets for antimetabolities, as
interference in cell metabolism has a greater effect when rapid cell
division is taking place. The toxic effect is directed at all prolifer-
ating cells, not just cancer cells, accounting for some of the side-
effects on the haematopoietic system and epithelial tissues that are
often seen with anti-cancer agents.
The pathways of folate metabolism, essential to cell reproduc-
tion, are shown in Figure 1. These provide many targets for inter-
vention. Drugs that act on dihydrofolate reductase (DHFR),
methotrexate (reviewed by Jolivet et al, 1983) is the classical
example, will inhibit the synthesis both of purines and of pyrim-
idines. Other drugs may act specifically on purine or pyrimidine
synthesis. For example, raltitrexed acts directly on thymidylate
synthase (TS) (Ward et al, 1992), while lometrexol (Beardsley et
al, 1989) affects only purine synthesis by inhibiting glycinamide
ribonucleotide formyltransferase (GARFT).
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MTA (LY231514) is a folate analogue in which the 6,6-fused
pteridine ring system of folic acid is replaced by a pyrrolo[2,3-d]-
pyrimidine ring (Figure 2) (Taylor et al, 1992). This compound
emerged from Lilly's programme of synthesis of potential
GARFT inhibitors. It was discovered that one of the enantiomers
ofracemic lometrexol was difficult to synthesize, and replacement
of the six-membered ring with an aromatic five-membered ring
was proposed to get around this problem. The resulting compound
was shown to potently inhibit both DHFR and TS, as well as
inhibiting both GARFT and aminoimidazole carboxamide ribonu-
cleotide formyltransferase (AICARFT) at micromolar concentra-
tions (Shih et al, 1997). Because of this variety of actions, it has
been termed a multi-targeted antifolate, or MTA. It is a classical
antifolate, which is converted to polyglutamated derivatives in the
cell. The polyglutamated forms have been shown to have much
greater inhibitory activity against isolated TS and GARFT than the
parent compound, although the inhibition of DHFR was unaf-
fected by polyglutamation (Table 1).
Drug resistance to antifolates arises in tumour cells through a
variety ofmechanisms (O'Connor et al, 1992; Gorlick et al, 1996).
Antifolates with multiple modes ofaction have been proposed as a
potential solution to the problem of resistance. A drug with a
variety ofmechanisms ofaction may continue to have anti-tumour
activity whereas a single-activity agent might not (Calvert et al,
1980). Although MTA has been shown to inhibit DHFR, TS and
GARFT in vitro, it has yet to be established whether its in vivo
activity depends only on inhibition ofTS, or whether other loci are
involved. It does appear, however, that TS inhibition will play a
major role in the clinical activity of MTA.
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Figure 1 Folate metabolite pathways. DHFR, dihydrofolate reductase; FH4, tetrahydrofolate; FH2, dihydrofolate; Glue polyglutamate; CYCLO, cyclo-5,10-
methenyltetrahydrofolate cyclooxygenase; GAR, glycinamide ribonucleotide formyltransferase; AICAR, aminoimidazole carboxamide ribonucleotide
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Figure 2 Structures of lometrexol and MTA
MTA has been shown to have activity against a range ofhuman
cell lines, including CCRF-CEM leukaemia cells, colon, renal,
hepatoma and lung cancer (Von Hoff, 1988). In vivo activity has
been demonstrated against a thymidine kinase-deficient murine
lymphoma model (Schultz et al, 1996). Toxicity in mice was
minimal (Eli Lilly and Co., personal communication) and as a
result of its preclinical activity, MTA was selected for phase I
clinical trials.
Table 1 K values of MTA and its polyglutamate (nM)
Enzyme MTA (parent compound) MTA-(glu)5
TS 109 1.3
DHFR 7.0 7.2
GARFT 9300 65
TS, thymidylate synthase; DHFR, dihydrofolate reductase; GARFT,
glycinamide ribonucleotide formyltransferase.
Phase I clinical trials of MTA: 3-weekly schedule
MTA has been investigated in three dose- and schedule-finding
phase I clinical trials. In one of these, carried out in San Antonio,
Texas, MTA was administered once every 3 weeks as a 10-min i.v.
infusion (Rinaldi et al, 1996). The modified continual reassess-
ment method (MCRM) was used (Faries, 1994), which involved
treating only one patient at each minimally toxic dose level, but
continuing to add patients at dose levels at which significant toxi-
city was observed. This method allows more patients to be treated
with doses that are likely to be effective. Doses were in the range
50-700 mg m-2. A summary of patient characteristics is shown in
Table 2.
Six patients were treated at the highest dose, at which the drug
was found to have significant side-effects, including WHO grade 4
neutropenia (three patients), grade 3 or 4 thrombocytopenia (three
patients) and grade 2 mucositis (two patients). These effects were
considered to constitute a maximum-tolerated dose (MTD). The
recommended dose for phase II trials was 600 mg m-2, and 20
patients were treated at this level. Toxicities, summarized in Table 3,
were mainly haematological. Thrombocytopenia and neutropenia
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Table 2 Phase clinical trials of MTA: patient characteristics
Schedule 3-Weekly Weekly x 4 Daily x 5
(Day 1 every 21 days) (Days 1, 8, 15, 21 every 42 days) (Days 1-5 every 21 days)
Patients entered/evaluable 37/37 25/24 38/37
Male/female 27/10 11/13 19/19
Age range (median) (years) 30-74 (59) 20-82 (59) 33-72 (58)
Performance status 16/4/14 12/11/1 7/26/5
(Scale) (KPS 100/90/80) (WHO 0/1/2) (WHO 0/1/2)
Tumour site
Colorectal 25 17 17
Pancreatic 3 0 4
Other 9 8 12
Prior chemotherapy 33 24 26
Prior radiotherapy NA 8 11
Table 3 Phase trials: responses and toxicities (course 1)
Toxicity (grade) 3-Weekly (patients) Weekly x 4 (patients) Daily x 5 (patients,
(4 mg m-2 dose)
Neutropenia (3/4) 4/5 5/5 1/1
Thrombocytopenia (3/4) 1/1 1/1 0/0
Mucositis (1/2) 0/2 4/0 2/0
Dermatitis (1/2) 2/10 1/0
Anaemia (1/2) 4/5 8/7
Nausea/vomiting (1/2) 3/2 9/2
Transaminase elevations (1/2) 7/1 3/1 2/3
Fatigue (1/2) 8/2 10/1
Complete response 0 0 0
Partial response 2 (Pancreas) 0 0
2 (Colorectal)
Minor response 6 (Colorectal) 2 (Colorectal) 2 (NSCLC, colorectal)
were dose limiting, although non-haematological toxicities, such as
fatigue, mucositis, skin rash and nausea, were also seen.
Pharmacokinetic parameters were measured in this study
(Woodworth et al, 1997). Plasma and urine samples were taken
from all patients after the first course of treatment. The mean
harmonic half-life was 5.07 h, and 78% of the drug was excreted
unchanged in the urine. Partial responses were observed in two
patients with colorectal cancer and two patients with pancreatic
cancer. Three of these patients had received prior TS inhibitors
(5-FU, FUdR or raltitrexed). Minor responses were seen in six
patients with colorectal cancer.
Weekly schedule
In a second phase I study, MTA was administered on a weekly
basis, with doses ranging from 10 to 40 mg m-2 given by 10-min
i.v. infusion every week for 4 weeks and the cycle repeated every 6
weeks (Rinaldi et al, 1995). Patients were included who had given
written informed consent and met the following criteria: WHO
performance status <3; life expectancy of more than 12 weeks;
measurable tumour; adequate bone marrow, platelet count and
liver function. As before, dose escalation was by the MCRM and
commenced with 10 mg m-2.
Of the 25 patients recruited, one was not evaluable because of a
small bowel obstruction that developed after the first dose of
LY231514, and the patient subsequently withdrew from the study.
The characteristics ofthe remaining patients are shown in Table 2.
Patients received between one and seven courses oftreatment, and
a total of58 courses were given. Significant toxicity, mainly grade
3 and 4 neutropenia, was seen in patients who received the
40 mg m-2 dose and, as toxicity was minimal at the 20 mg m-2
dose, an additional dose of 30 mg m-2 was added. Ten patients
were treated at this level, which was determined to be the recom-
mended dose for phase II. Toxicities are summarized in Table 3.
Neutropenia was dose-limiting, but non-haematological toxicities
were mild. Two minor responses were observed, in patients with
refractory, previously treated colorectal cancer. This schedule was
not thought to be suitable for evaluation in a phase II setting as
myelosuppression often precluded the administration of the third
and fourth doses in each course.
Daily schedule
In the third phase I trial, carried out in the UK, 38 patients with ten
different tumour types were given MTA on a daily basis for 5 days,
every 3 weeks (McDonald et al, 1996). Patient characteristics are
shown in Table 2. Doses ranged from 0.2 to 5.2 mg m-2, with the
number of courses ranging from one to ten. Of the 38 patients
entered, 37 were evaluable for toxicity. The main toxicities
observed were myelosuppression and an elevation in transaminase
levels. Significant thrombocytopenia was not seen and non-
haematological effects were mild. Toxicities are summarized in
Table 3. Two patients had minor responses, one with non-small-
cell lung cancer (NSCLC) and the other colorectal cancer.
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Table 4 Phase II trials of MTA: patient characteristics and responses by tumour type
Study Pancreas Breast NSCLC NSCLC Colorectal Colorectal
USA UK Canada S.Africa/Australia USA Canada
Patients entered 44 22 19 19 41 33
Evaluable for response/toxicity 18/39 18/19 12/15 10/12 17/41 30/33
Male/female 12/7 25/16 17/16
Age range (median) (years) 37-77 (60) 43-81 (54) (63) (59) (68)
Stage III/IV 7/37
Performance status 0-1 19 0-2 28/11/1 13/18/2
(Scale) (ECOG) (ECOG 0/1) WHO (ECOG 0/1/2) (ECOG 0/1/2)
Prior chemotherapy 0 14 0 0 26 9
Prior radiotherapy 0 17 0 0 11 3
Responses
Complete 1 0 0 0 1 1
Partial 1 6 3 3 3 6
Phase 11 clinical trials
Although phase II trials ofMTA are still in progress, some prelim-
inary results are available. Phase II trials are being carried out in
patients with solid tumours, in particular, cancers ofthe breast and
pancreas, as well as colorectal and NSCL cancers. Initially, the 3-
weekly schedule (600 mg m-2) was chosen for phase II studies
because of the ability to give repeat doses, the convenience of the
schedule and because partial responses were seen in the phase I
trial using this schedule.
In order to investigate the results seen in phase I trials in which
partial and minor responses were seen in patients with advanced
pancreatic cancer, a study was initiated in the USA that recruited 44
patients with histologically confirmed, unresectable pancreatic
cancer (Miller et al, 1997). Phase II patient characteristics are
summarized in Table 4. MTA (600 mg m-2) was given as a 10-min
infusion every 21 days and was generally well tolerated. Dose reduc-
tions were required in 17% ofpatients. Cutaneous toxicity, often seen
in antifolate therapy, was the most common toxicity, occurring in
over half of the patients, but was not life-threatening and was
reported to be alleviated by dexamethasone. Other significant toxici-
ties were haematological in nature. Grade 3/4 granulocytopenia was
seen in 42% of patients, while elevation of transaminase levels was
seen in less than 20%. One complete response and one partial
response have been seen in this trial, out of 18 patients who are
evaluable at the time of writing. Another six patients have stable
disease, an encouraging result in a disease that is generally resistant
to treatment and in which responses tend to be infrequent.
A study of MTA in locally advanced and metastatic breast
cancer is ongoing (Smith et al, 1997). Of 22 patients recruited to
this study, 19 are evaluable for toxicity and 18 for response. Grade
3/4 thrombocytopenia and neutropenia were the major toxicities
seen, the former in 41% of patients and the latter in 18% of
patients. Other toxicities observed included grade 3/4 skin reac-
tions in 16% of patients and grade 2/3 elevations in ALT values,
seen in 84% ofpatients. Partial responses were seen in six patients,
five of whom had previously received chemotherapy, including
docetaxel, 5-FU and gemcitabine.
MTA is also being studied in the treatment ofNSCLC. Two trials
are ongoing, one in Canada and the other ajoint South African and
Australian study. The first ofthese, an NCIC study, has enrolled 19
patients to date, 12 of whom are evaluable for response and 15 for
toxicity (Rusthoven et al, 1997). Patients included had histologically
proven, stage III/IV disease and were chemonaive. As determined in
the phase I trials, the starting dose for the first three patients was
600 mg m-2, but toxicities observed at this dose led to a reduction in
the dose to 500 mg m-2. Grade 3/4neutropenia has been seen in 32%
ofpatients, along with elevated transaminase levels; this was shown
to be transient, as seen in trials ofother antifolates, such as CB 3717
(Calvert et al, 1986) and raltitrexed (Burris et al, 1994). Partial
responses were seen in three patients, for an overall response rate of
33%. In the secondtrial, 19 patients received MTA 600 mg m-2 once
every 3 weeks (Clarke et al, 1997). Of the ten patients eligible for
response assessment, three partial responses have been seen and the
remaining seven patients had stable disease. The principal grade 3/4
toxicity was neutropenia, which occurred in 42% ofpatients. Other
toxicities seen included grade 3/4 rash (17%), grade 3 nausea (8%)
and grade 4 vomiting (8%). Both these trials continue to accrue
patients.
Patients with metastatic colorectal cancer have also been treated
with MTA in two phase II studies carried out in the USA (John et
al, 1997) and Canada (Cripps et al, 1997). Prior adjuvant
chemotherapy was allowed in the USA study, as long as patients
had been untreated for one year before inclusion in the trial. Ofthe
41 patients entered into the trial, 32 had colon cancer and nine had
rectal cancer. All patients were evaluable for toxicity and 17 for
response. The major grade 3/4 toxicity observed was neutropenia,
seen in 56% of patients, while 16% and 12% of patients experi-
enced grade 3/4 thrombocytopenia and anaemia, respectively. Skin
reactions were common, occurring in 69% of patients, but were
rarely significant. A complete response was seen in one patient and
partial responses in three others, while seven patients had stable
disease. Ofthe 33 patients entered into the Canadian study, 24 were
chemonaive. The recommended phase II dose of 600 mg m-2 was
given to nine patients, but this was subsequently reduced to 500 mg
m-2 in the remaining 24 patients, when several early patients expe-
rienced toxicities requiring dose reduction. One complete response
and six partial responses were seen in these patients, for an overall
response rate of 23% (95% CI 10-42%). Grade 3/4 neutropenia
was seen in 45% of patients and grade 3/4 thrombocytopenia in
12% of patients. Grade 3 rash was seen in 40% of patients. The
activity of MTA in colorectal cancer demonstrated in these studies
is to be further investigated in larger phase III studies.
In conclusion, although these phase II results are preliminary,
MTA appears to show promising activity in the treatment ofseveral
solid tumours, including breast, colorectal, pancreas and NSCL
cancers. Further data are required before conclusions can be drawn
regarding the absolute efficacy, but first indications are favourable.
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THE FUTURE FOR MTA
MTA is a new antifolate with a novel pharmacological profile.
Preclinical studies have shown that it has several potential modes of
action, including inhibition ofTS, GARFT and DHFR.
Results of single-agent phase I and II trials with MTA have
shown that the most common toxicities, i.e. myelosuppression and
skin reactions, were generally tolerable and manageable. The
dose-limiting toxicities were usually haematological. Preliminary
indications are that MTA is effective against solid tumours,
including NSCLC, colorectal, breast and pancreatic cancers, and
phase II trials are ongoing that will assess the efficacy of the drug
against these specific tumours.
The activity of MTA in NSCLC is very encouraging, given that
there has been little activity seen for other antifolates in this
disease. A randomized trial comparing vinorelbine with 5-FU and
leucovorin concluded that 5-FU had negligible activity against
NSCLC (3%) in patients with stage IV disease (Crawford et al,
1996). Three phase II trials ofedatrexate showed response rates of
32% (Shum et al, 1988), 13% (Souhami et al, 1992) and 10% (Lee
et al, 1990). A subsequent phase III trial in 673 patients, which
compared edatrexate, mitomycin and vinblastine (EMV) with
mitomycin and vinblastine (MV), failed to show improved
survival in patients treated with EMV, although the response rate
in the EMV arm was higher (24% compared with 16%) (Comis et
al, 1994). Myelosuppression and stomatitis were more common in
patients receiving the EMV combination. In a study of trime-
trexate, no major objective responses were seen in patients with
stage III and IV disease (Kris et al, 1989).
It is also possible that MTA will prove to be an effective compo-
nent in combination therapy and, to this end, trials are planned that
will study the effects of the drug in combination with 5-FU or
gemcitabine. The latter combination was suggested by research that
has shown that pretreatment of HT29 colon carcinoma cells with
MTA results in increased antiproliferative activity of gemcitabine
(Tonkinson et al, 1996). A phase I trial is underway to investigate
the combination of MTA and cisplatin in patients with solid
tumours (Thoedtmann et al, 1997). Trials are also planned to inves-
tigate the effect offolates on the toxicities seen with MTA, based on
the observation that animals given folate supplements were better
able to tolerate treatment with MTA, with fewer side-effects
(Worzalla et al, 1997). Trials are also planned for combinations
with gemcitabine, irinotecan, oxaliplatin, carboplatin, doxorubicin
and docetaxel, and the combination of MTA with radiotherapy will
also be studied, once preclinical data have been generated.
The effect of MTA in other cancers is also under investigation.
Trials are underway or planned in which MTA is given to patients
with renal, bladder, cervical and oesophageal cancers, although
results are not yet available from these studies. Other trials are
planned in which MTA will be used to treat patients with ovarian and
head and neck cancers, and the results of these, and other trials
nearing completion, are awaited with interest. Initial indications
suggest that MTA will find aplace in the anti-cancer armamentarium.
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